• FOLLOW

    ADVANCES & NOVEL INNOVATIONS IN

    CELL AND GENE THERAPY

    Download Brochure

    -509Days -15Hours -31Minutes -3Seconds
  • SHOWCASE

    YOUR RESEARCH BEFORE

    GLOBAL BIOMEDICAL LEADERS

    Download Brochure

    -509Days -15Hours -31Minutes -3Seconds
  • MEET

    THE TOP MINDS WORKING ON

    CELL AND GENE THERAPY
    BREAKTHROUGHS

    Download Brochure

    -509Days -15Hours -31Minutes -3Seconds

Overview

Recent advances in Cell and Gene Therapy (CGT) have opened up possibilities of how advanced therapies that insert genes and use cells, are on the brink of transforming medicine and curing disease. Since the first human gene transfer experiment in 1989, to the latest advances in the last three decades, the past few years have seen, ATMPs being approved, both in the United States and The EU.

A good part of this decade has been exciting and productive for cell and gene based therapeutics, with biomedical and bio pharma companies celebrating unprecedented success, including record approvals, spanning a variety of disease areas. The success of CGT has largely been driven by improvements in non-viral and viral gene transfer vectors. In addition to the many advances in therapeutics, we also saw heightened activity in several potentially disruptive advanced in biomedicine, including advanced cell engineering, gene therapy, CAR-T, and microbiome therapeutics.

Excellence: The Cell and Gene Therapy Conclave is designed as a platform to gain valuable insights into the most innovative developments in CGT.

WHY ATTEND?

Meet over 150 delegates

representing leading biotechnology companies, global pharmaceutical organisations, and internationally renowned academic institutions.

Discuss key issues

concerning Cell and Gene Therapy in the broader context of scalable manufacturing.

Over 20 presentations

case studies and panel discussions focussed on Cell & Gene Therapy development and research.

Topics of Discussion

  • Perspectives from the Healthcare Regulatory Authority on Standardisation and Control

  • The current state of pay and novel advances in Cell and Gene based therapies

  • Cellular Standards and Accreditation

  • Scalable Cell-Based Immunotherapy Manufacture

  • Development and Production of Next Generation Viral Vectors

  • Exploring advantages of a DCM (Decentralized Model) for CGT manufacturing

  • Scalabe Autologus CAR T Cell Product Production

  • Regulatory and Safety Aspects of Cell and Gene Therapy

  • Go-To Market Strategies for Advanced Therapy Medicinal Products (ATMPs)

  • Redefining Supply Chain Paradigm in CGT

  • A Comparative Analysis of Novel Gene Editing Technologies like CRISPR TALEN, RNAi

  • Translational Challenges and Classification of Technologies

Please fill in this form to download agenda.